Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04386057 · ClinicalTrials.gov registry record · Phase 2
LY3214996 +/- HCQ in Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer and Advanced Cancer, sponsored by Kimberly Perez, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT04386057: Completed Phase 2 study of Pancreatic Cancer and Advanced Cancer, sponsored by Kimberly Perez, MD.
NCT04386057 is a Phase 2 study of Pancreatic Cancer and Advanced Cancer that has completed, run by Kimberly Perez, MD. The registered enrollment target is 52 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04386057, a Phase 2 study of Pancreatic Cancer and Advanced Cancer, has completed, sponsored by Kimberly Perez, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
Primary Outcome
Anti-tumor activity will be measured via disease control rate (DCR), which will be defined as the proportion of patients with complete response (CR), partial response (PR) or stable disease (SD) that persists for ≥ 4 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the diameters of target lesions; Stable Dis
Conditions Studied
Interventions
- DRUG Hydroxychloroquine Sulfate
- DRUG LY3214996
Study Locations (4)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-05-27 |
| Est. Completion | 2024-02-05 |
| Phase | Phase 2 |
What the finished NCT04386057 record still lists
NCT04386057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hydroxychloroquine Sulfate is the first listed.
NCT04386057 reports a single indexed study location in Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04386057 about?
NCT04386057 is a clinical study titled "LY3214996 +/- HCQ in Pancreatic Cancer". This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
What is the current status of trial NCT04386057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-05-27. Estimated completion is 2024-02-05.
What conditions does trial NCT04386057 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Cancer.
What interventions are being tested in trial NCT04386057?
The interventions under investigation include: Hydroxychloroquine Sulfate (DRUG), LY3214996 (DRUG).
Who is sponsoring clinical trial NCT04386057?
This trial is sponsored by Kimberly Perez, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04386057 being conducted?
This trial has 4 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04386057's enrollment target sits among peer trials
52 150th of 278 higher than 129 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI